SCHEMBL6764641

SCHEMBL6764641

CC(O)(CS(=O)(=O)c1ccc(NC(=O)c2ccc(Cl)cc2)cc1)C(=O)NO

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.54
HSD17B10 Q99714 1/20 0.54
NPC1 O15118 2/20 0.53
RAB9A P51151 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
CA1 P00915 2/20 0.52
CA12 O43570 1/20 0.52
CA9 Q16790 1/20 0.52
ENPP1 P22413 5/20 0.52
ENPP3 O14638 4/20 0.52
PRMT1 Q99873 2/20 0.51
MEN1 O00255 5/20 0.48
KMT2A Q03164 5/20 0.48
ENPP2 Q13822 3/20 0.48
CA2 P00918 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6764639 0.88 PRMT1 (0.55) MAPTSMN1; SMN2CA1CA12CA9
SCHEMBL6768091 0.87 MAPT (0.53) MAPTNPC1RAB9ASMN1; SMN2MEN1
SCHEMBL6773991 0.86 RAB9A (0.54) MAPTRAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL6764678 0.85 ENPP1 (0.53) NPC1RAB9ACA1ENPP1MEN1
SCHEMBL6768589 0.85 AR (0.46) MAPTCYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL6768715 0.84 KDM4E (0.57) MAPTNPC1RAB9ASMN1; SMN2CA1
SCHEMBL6767959 0.83 MAPT (0.55) MAPTHSD17B10NPC1RAB9ASMN1; SMN2
SCHEMBL6764633 0.81 NPC1 (0.52) MAPTNPC1RAB9ASMN1; SMN2MEN1
SCHEMBL6767671 0.80 MAPT (0.52) MAPTNPC1SMN1; SMN2CA1CA12
SCHEMBL6768704 0.80 CYP2C19 (0.50) MAPTNPC1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6716844-B2 ENZYME INHIBITORS; ANTIINFLAMMATORY AGENTS, ANTIARTHRITIC AGENTS PHARMACIA CORPORATION 2004-04-06 US disclosed
EP-0984959-B1 AROMATIC SULFONYL ALPHA-HYDROXY HYDROXAMIC ACID COMPOUNDS PHARMACIA CORP (US) 2003-09-24 EP disclosed
US-20020173508-A1 Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds PHARMACIA CORPORATION 2002-11-21 US disclosed
US-6362183-B1 PROTEASE INHIBITORS; RHEUMATIC DISEASES; ANTITUMOR AGENTS G. D. SEARLE & COMPANY 2002-03-26 US disclosed
EP-0984959-A4 AROMATIC SULFONYL ALPHA-HYDROXY HYDROXAMIC ACID COMPOUNDS MONSANTO CO (US) 2001-05-02 EP disclosed
EP-0984959-A1 AROMATIC SULFONYL ALPHA-HYDROXY HYDROXAMIC ACID COMPOUNDS MONSANTO COMPANY (US) 2000-03-15 EP disclosed
WO-1998039326-A1 AROMATIC SULFONYL ALPHA-HYDROXY HYDROXAMIC ACID COMPOUNDS MONSANTO COMPANY (US) 1998-09-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020173508-A1 Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds MMP1, MMP2, MMP3 MAPT 4266/4885HSD17B10 551/4885NPC1 2284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.